Infectious Disease Doctor: David W. Hecht, MD | Loyola Medicine

David W. Hecht, MD, IDSA

David Hecht, MD

Medicine

Infectious Disease
Professor

Languages Spoken

English

Clinical Expertise

  • AIDS
  • HIV

About Dr. Hecht

Interests

Medical Education

Medical School
Loyola University Chicago Stritch School of Medicine
Residency
University of Minnesota Hospital and Clinics - Internal Medicine: General
Fellowship
  • Tufts University Affiliated Hospitals - Infectious Diseases

Board Certification

American Board of Internal Medicine, Infectious Disease
Infectious Disease, American Board of Internal Medicine Subspecialty

Research

  • Comparative genomics analysis of Clostridium difficile epidemic strain DH/NAP11/106 Kociolek, L. K.; Gerding, D. N.; Hecht, D. W.; Ozer, E. A., Microbes and Infection
  • Whole-genome analysis reveals the evolution and transmission of an MDR DH/NAP11/106 Clostridium difficile clone in a paediatric hospital Kociolek, L. K.; Ozer, E. A.; Gerding, D. N.; Hecht, D. W.; Patel, S. J.; Hauser, A. R., The Journal of antimicrobial chemotherapy
  • Complete Genome Sequence of Clostridioides difficile Epidemic Strain DH/NAP11/106/ST-42 Isolated from Stool from a Pediatric Patient with Diarrhea, Ozer, E. A.; Hauser, A. R.; Gerding, D. N.; Espinosa, R. O.; Hecht, D. W.; Kociolek, L. K., Genome announcements
View All ResearchShow Less
  • Trends in antimicrobial resistance among Bacteroides species and Parabacteroides species in the United States from 2010-2012 with comparison to 2008-2009 Snydman, D. R.; Jacobus, N. V.; McDermott, L. A.; Goldstein, E. J.; Harrell, L.; Jenkins, S. G.; Newton, D.; Patel, R.; Hecht, D. W., Anaerobe
  • Changes in the antibiotic susceptibility of anaerobic bacteria from 2007-2009 to 2010-2012 based on the CLSI methodology Hastey, C. J.; Boyd, H.; Schuetz, A. N.; Anderson, K.; Citron, D. M.; Dzink-Fox, J.; Hackel, M.; Hecht, D. W.; Jacobus, N. V.; Jenkins, S. G.; Karlsson, M.; Knapp, C. C.; Koeth, L. M.; Wexler, H.; Roe-Carpenter, D. E.; From the Ad Hoc Working Group on Antimicrobial Susceptibility Testing of Anaerobic Bacteria of CLSI, Anaerobe
  • Differences in the Molecular Epidemiology and Antibiotic Susceptibility of Clostridium difficile Isolates in Pediatric and Adult Patients Kociolek, L. K.; Gerding, D. N.; Osmolski, J. R.; Patel, S. J.; Snydman, D. R.; McDermott, L. A.; Hecht, D. W., Antimicrobial Agents and Chemotherapy
  • Emergence and evolution of an international cluster of MDR Bacteroides fragilis isolates Soki, J.; Hedberg, M.; Patrick, S.; Balint, B.; Herczeg, R.; Nagy, I.; Hecht, D. W.; Nagy, E.; Urban, E., The Journal of antimicrobial chemotherapy
  • Susceptibility of Clostridium difficile isolates from a Phase 2 clinical trial of cadazolid and vancomycin in C. difficile infection Gerding, D. N.; Hecht, D. W.; Louie, T.; Nord, C. E.; Talbot, G. H.; Cornely, O. A.; Buitrago, M.; Best, E.; Sambol, S.; Osmolski, J. R.; Kracker, H.; Locher, H. H.; Charef, P.; Wilcox, M., The Journal of antimicrobial chemotherapy
  • Diversity of Clostridium perfringens isolates from various sources and prevalence of conjugative plasmids Park, M.; Deck, J.; Foley, S. L.; Nayak, R.; Songer, J. G.; Seibel, J. R.; Khan, S. A.; Rooney, A. P.; Hecht, D. W.; Rafii, F., Anaerobe
  • Fluoroquinolone and Macrolide Exposure Predict Clostridium difficile Infection (CDI) with the Highly Fluoroquinolone- and Macrolide-Resistant Epidemic C. difficile Strain BI/NAP1/027, Wieczorkiewicz, J. T.; Lopansri, B. K.; Cheknis, A.; Osmolski, J. R.; Hecht, D. W.; Gerding, D. N.; Johnson, S., Antimicrobial Agents and Chemotherapy
  • Kibdelomycin is a potent and selective agent against toxigenic Clostridium difficile Miesel, L.; Hecht, D. W.; Osmolski, J. R.; Gerding, D.; Flattery, A.; Li, F.; Lan, J.; Lipari, P.; Polishook, J. D.; Liang, L.; Liu, J.; Olsen, D. B.; Singh, S. B., Antimicrobial Agents and Chemotherapy
  • Update on resistance of Bacteroides fragilis group and related species with special attention to carbapenems 2006-2009 Snydman, D. R.; Jacobus, N. V.; McDermott, L. A.; Golan, Y.; Goldstein, E. J.; Harrell, L.; Jenkins, S.; Newton, D.; Pierson, C.; Rosenblatt, J.; Venezia, R.; Gorbach, S. L.; Queenan, A. M.; Hecht, D. W., Anaerobe
  • Lessons learned from the anaerobe survey: historical perspective and review of the most recent data (2005-2007). Snydman, D. R.; Jacobus, N. V.; McDermott, L. A.; Golan, Y.; Hecht, D. W.; Goldstein, E. J.; Harrell, L.; Jenkins, S.; Newton, D.; Pierson, C.; Rihs, J. D.; Yu, V. L.; Venezia, R.; Finegold, S. M.; Rosenblatt, J. E.; Gorbach, S. L., Clinical Infectious Diseases
  • Phenotypic and genotypic characterization of tetracycline and minocycline resistance in Clostridium perfringens Park, M.; Rooney, A. P.; Hecht, D. W.; Li, J.; McClane, B. A.; Nayak, R.; Paine, D. D.; Rafii, F., Archives of Microbiology
  • The novel antibacterial drug XF-70 is a potent inhibitor of Staphylococcus aureus infection of the burn wound. Hurtuk, M. G.; He, L. K.; Szilagyi, A.; Gamelli, R. L.; Hecht, D. W.; Kennedy, R. H.; Rhys-Williams, W.; Love, W. G.; Shankar, R., Journal of Burn Care & Research
  • Rifaximin Redux: treatment of recurrent Clostridium difficile infections with rifaximin immediately post-vancomycin treatment. Johnson, S.; Schriever, C.; Patel, U.; Patel, T.; Hecht, D. W.; Gerding, D. N., Anaerobe
  • Association of enterotoxigenic Bacteroides fragilis infection with inflammatory diarrhea. Sears, C. L.; Islam, S.; Saha, A.; Arjumand, M.; Alam, N. H.; Faruque, A. S.; Salam, M. A.; Shin, J.; Hecht, D.; Weintraub, A.; Sack, R. B.; Qadri, F., Clinical Infectious Diseases
  • Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile. O'Connor, J. R.; Galang, M. A.; Sambol, S. P.; Hecht, D. W.; Vedantam, G.; Gerding, D. N.; Johnson, S., Antimicrobial Agents & Chemotherapy
  • Characterization of BctA a mating apparatus protein required for transfer of the Bacteroides fragilis conjugal element BTF-37., Hecht, D. W.; Kos, I. M.; Knopf, S. E.; Vedantam, G., Research in microbiology
  • In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004. Hecht, D. W.; Galang, M. A.; Sambol, S. P.; Osmolski, J. R.; Johnson, S.; Gerding, D. N., Antimicrobial Agents & Chemotherapy
  • Interaction of Bacteroides fragilis pLV22a relaxase and transfer DNA with Escherichia coli RP4-TraG coupling protein. Thomas, J.; Hecht, D. W., Molecular microbiology
  • Anaerobes: antibiotic resistance clinical significance, and the role of susceptibility testing, Hecht, D. W., Anaerobe
  • Bacteroides fragilis mobilizable transposon Tn5520 requires a 71 base pair origin of transfer sequence and a single mobilization protein for relaxosome formation during conjugation. Vedantam, G.; Knopf, S.; Hecht, D. W., Molecular microbiology
  • Implementing computerized provider order entry with an existing clinical information system. Barron, W. M.; Reed, R. L.; Forsythe, S.; Hecht, D.; Glen, J.; Murphy, B.; Lach, R.; Flores, S.; Tu, J.; Concklin, M., Joint Commission Journal on Quality & Patient Safety
  • Information technology. Implementing computerized provider order entry with an existing clinical information system Barron, W. M.; Reed, R. L.; Forsythe, S.; Hecht, D.; Glen, J.; Murphy, B.; Lach, R.; Flores, S.; Tu, J.; Concklin, M., Joint Commission Journal on Quality & Patient Safety
  • Activities of garenoxacin (BMS-284756) and other agents against anaerobic clinical isolates. Hecht, D. W.; Osmolski, J. R., Antimicrobial Agents & Chemotherapy
  • Antibiotics and anaerobes of gut origin Vedantam, G.; Hecht, D. W., Current opinion in microbiology